FAQ · safety and regulatory record
CJC-1295: frequently asked questions, answered from the record
Direct answers on the safety profile, the regulatory status, the side-effect literature, and the questions people most often ask about CJC-1295 — each cited where it makes a quantitative claim.
Reported and Theoretical Side Effects of CJC-1295
The reported and theoretical side effects of CJC-1295 are mostly extrapolated from growth-hormone-axis stimulation generally, because controlled side-effect data specific to CJC-1295 in healthy adults are lacking. The concerns that recur in the literature are fluid retention and edema — growth hormone increases renal sodium reabsorption — and effects on insulin sensitivity, alongside the epidemiologic concern that sustained IGF-1 elevation is associated with a modestly increased risk of certain cancers [11].
That IGF-1 concern is not abstract for this compound specifically: the DAC variant kept IGF-1 elevated up to 28 days after repeat dosing [1], so the sustained-elevation profile the epidemiology worries about is exactly what the long-acting form produces. The FDA also cited immunogenicity and other safety concerns for growth-hormone secretagogues, including CJC-1295, in briefing materials for the 2024 Pharmacy Compounding Advisory Committee [1]. None of this is a controlled safety dataset; it is the honest perimeter of what is known and what is plausibly concerning.
Frequently asked questions about CJC-1295
What is CJC-1295?
A synthetic long-acting analog of growth-hormone-releasing hormone, built on hGRF(1-29) with four protease-resistant substitutions. The DAC variant adds covalent serum-albumin binding for a multi-day half-life; the no-DAC form, Modified GRF 1-29, is short-acting. It is an unapproved research chemical, not approved for human use.
What does CJC-1295 do?
In studies it binds the pituitary GHRH receptor and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1. In healthy adults a single dose elevated growth hormone and IGF-1 for days [1]. It acts on the GH/IGF-1 axis rather than supplying a hormone directly.
Is CJC-1295 safe?
Safety in healthy adults is not established; human data are limited to short early-PK studies. Sustained GH/IGF-1 elevation raises theoretical concerns — epidemiology links higher IGF-1 to modestly increased risk of certain cancers [11] — and FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns [1].
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA or any major regulator for human use; it is handled as a research chemical. It was reviewed at the 2024 FDA Pharmacy Compounding Advisory Committee and not recommended for the 503A compounding bulks list, with immunogenicity and other safety concerns cited [1].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog, not an anabolic-androgenic steroid. It acts upstream on the pituitary GHRH receptor to stimulate the body's own growth-hormone release rather than supplying a steroid hormone [1].
Are CJC-1295 peptides safe?
Long-term safety in healthy adults is unestablished. Theoretical concerns center on sustained GH/IGF-1 elevation — fluid retention, effects on insulin sensitivity, and the IGF-1/cancer-risk epidemiology [11] — plus immunogenicity concerns the FDA cited in 2024 [1].
What are the side effects of CJC-1295?
Most reported and theoretical effects are extrapolated from GH-axis stimulation: fluid retention and edema, since growth hormone increases renal sodium reabsorption, and effects on insulin sensitivity, with epidemiologic concern about sustained IGF-1 elevation [11]. Controlled side-effect data specific to CJC-1295 in healthy adults are lacking.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and the published CJC-1295 literature does not establish a direct effect on testosterone [1]. Claims either way are not supported by controlled human data on CJC-1295.
Does CJC-1295 lower testosterone?
There is no controlled human evidence that CJC-1295 lowers testosterone; it targets the GHRH receptor and the downstream GH/IGF-1 axis rather than the hypothalamic-pituitary-gonadal axis [1]. The published literature does not document a testosterone-lowering effect.
Are CJC-1295 peptides safe?
Long-term human safety is not established. The compound has only early-phase PK data, and theoretical risks follow from sustained GH/IGF-1 elevation — including the IGF-1/cancer-risk epidemiology [11] — together with the immunogenicity concerns the FDA cited in 2024 [1].
Are peptides safer than TRT?
This comparison cannot be made from the CJC-1295 evidence base. CJC-1295 is an unapproved research chemical with no long-term human safety data, whereas approved GHRH analogs such as tesamorelin and testosterone therapy have defined, studied indications. 'Safer' is not established for unapproved GH-axis peptides [9].